874143-67-6

Basic information

• Product Name: 6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine
• Synonyms: 6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine;6-CHLORO-N-(PYRIDIN-2-YLMETHYL)PYRAZIN-2-AMINE
• CAS NO: 874143-67-6
• Molecular Formula: C10H9ClN4
• Molecular Weight: 220.65826
• Mol File: 874143-67-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: 107-108.5 °C
• Boiling Point: 371.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.368±0.06 g/cm3(Predicted)
• PKA: 4.34±0.12(Predicted)
• CAS DataBase Reference: 6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine(874143-67-6)
• EPA Substance Registry System: 6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine(874143-67-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 874143-67-6(Hazardous Substances Data)

Usage

Chemical compound

6-Chloro-N-(2-pyridinylmethyl)-2-pyrazinamine

Classification

Pyrazinamine derivative

Structural features

Pyridine-containing compound with a chlorine atom attached to the sixth carbon of the pyrazine ring

Pharmaceutical applications

Potential use in the treatment of tuberculosis, similar to pyrazinamide

Biological interactions

Presence of a pyridine moiety suggests potential interactions with biological systems and pharmaceutical targets

Potential for further study

Molecule of interest for further research and development in pharmaceutical applications

Upstream product

• 3731-51-9 2-(Aminomethyl)pyridine 
• 4774-14-5 2,6-dichloropyrazine 

Relevant articles and documents

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

B-RAF, a serine/threonine kinase, plays an important role in the development of certain classes of cancer, especially melanoma. As a result of high-throughput screening of a 23,000 compound library, 2-(3,4,5- trimethoxyphenylamino)-6-(3-acetamidophenyl)pyrazine, 1, was identified as a low micromolar (IC50 = 3.5 μM) B-RAF inhibitor. This compound was chosen as the starting point of a program aimed at producing potent inhibitors of B-RAF. We have synthesized a series of 40 novel compounds, which involved extensive modifications to the 2-(3,4,5-trimethoxyphenylamino) moiety (ring A) of 1. Their biological profiles against isolated B-RAF and mutated B-RAF in a cellular assay have been determined. These efforts led to the identification of two compounds exhibiting activities lower than 800 nM against B-RAF.